Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

In the claims:

1. (Original) An N-[(piperazinyl)hetaryl]arylsulfonamide compound of the general formula I



(I)

in which

R is oxygen, a group N-R^3 or a group $CR^{3a}R^{3b}$;

Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^a which is/are selected, independently of each other, from halogen, CN, NO_2, CO_2R^4, COR^5, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkyl, NH_2, NHR^6, NR^6R^7 and C_1-C_4-haloalkoxy;

Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^b, which is/are selected from halogen, NO_2, CN, CO_2R^4, COR^5, NH_2, NHR^6, NR^6R^7, C_1-C_6-alkyl, C_1-C_6-haloalkyl, C_1-C_6-alkoxy, C_1-C_6s22 -haloalkoxy, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkoxy, C_3-C_6-cycloalkyl-C_1-C_4-alkyl and C_1-C_4-haloalkyl, with it also being possible for two radicals R^b which are bonded to adjacent C atoms of Ar to be together C_3-C_4-alkylene;

n is 0, 1 or 2;

R^1 is hydrogen, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-hydroxyalkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_3-C_4-alkenyl or C_3-C_4-alkynyl;

R^2 is C_1-C_4-alkyl or, together with R^1, is C_2-C_5-alkylene or, in the case of n = 2, the two radicals R^2 can together be C_1-C_4-alkylene;

R^3 is hydrogen or C_1-C_4-alkyl;

R^{3a}, R^{3b} are, independently of each other, hydrogen or C_1-C_4-alkyl;

R^4 is C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_2-C_4-alkenyl C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_4-alkyl, phenyl or benzyl; and

R^5 is hydrogen, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_2-C_4-alkenyl C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_4-alkyl, phenyl or benzyl;

R^6, R^7 are each independently selected from C_1-C_4-alkyl, C_1-C_4-haloalkyl or together with the nitrogen to which they are bound form a saturated 3-, 4-, 5- or 6-membered heterocycle, which additionally may comprise an oxygen atom or an additional nitrogen atom as a ring member and which may carry 1, 2, 3 or 4 C_1-C_4 alkyl groups;

the N-oxides thereof and the physiologically tolerated acid addition salts of these compounds;

with the exception of the compounds: 4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide and 4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.

2. (Original) The compound as claimed in claim 1, wherein R is N-R^3 with R^3 being H or C_1-C_4-alkyl.

~~2~~ 3. (Currently Amended) The compound as claimed in claim 2, wherein

Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents

R^a which is/are selected, independently of each other, from halogen, CN, NO_2, CO_2R^4, COR^5, C_1-C_4-alkyl and C_1-C_4-haloalkyl and

Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^b, which is/are selected from halogen, NO_2, CN, CO_2R^4, COR^5, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C\pard plain $_1$-C_4-alkyl and C_1-C_4-haloalkyl, with it also being possible for two radicals R^b which are bonded to adjacent C atoms of Ar to be together C_3-C_4-alkylene.

~~3~~ 4. (Currently Amended) The compound as claimed in claim 1, in which the piperazine ring is bonded to the heteroaromatic radical Q in the para position in relation to the group R-SO_2-Ar.

~~4~~ 5. (Currently Amended) The compound as claimed in ~~one of the preceding claims~~ claim 1, in which Q is a radical of the formula



in which A_1, A_2 and A_3 are, independently of each other, N or CH, one or two of the variables A_1, A_2 and A_3 can also be C-R^a, k = 0 or 1 and R^a is selected from halogen, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, NH_2, NHR^6, NR^6R^7s22 and C_1-C_4-haloalkoxy, with A_1, A_2 and A_3 not simultaneously being N or simultaneously being selected from CH and C-R^a.

~~5~~ 6. (Currently Amended) The compound as claimed in claim ~~4~~ 5, in which A_3 is nitrogen, A_2 is CH and A_1 is N or CH and wherein the piperazine radical is located in the 2 position.

~~6~~ 7. (Currently Amended) The compound as claimed in claim ~~5~~ 6, in which Q is pyridin-2,5-diyl which carries the piperazine radical in the 2 position.

~~7~~ 8. (Currently Amended) The compound as claimed in claim ~~5~~ 6, in which Q is a radical of the formula



in which A_1 and A_2 are, independently of each other, N or CH and R^a is selected from , C_1-C_4-alkoxy, NH_2, NHR^6, NR^6R^7 and C_1-C_4-haloalkoxy.

~~8~~ 9. (Currently Amended) The compound as claimed in claim ~~7~~ 8, in which A_1 is N or CH and A_2 is CH and wherein the piperazine radical is located in the 2 position.

~~9~~ 10. (Currently Amended) The compound as claimed in ~~one of the preceding claims~~ claim 1, in which the radical Ar carries a substituent R^b in the para position and, where appropriate, a further substituent R^b in the meta position or in the ortho position, in each case based on the binding site of the sulfonamide group.

~~10~~ 11. (Currently Amended) The compound as claimed in ~~one of the preceding claims~~ claim 1, in which Ar is phenyl or pyridyl, which radicals possess, where appropriate, one or 2 R^b substituents.

~~11~~ 12. (Currently Amended) The compound as claimed in ~~one of the preceding claims~~ claim 1, in which R^1 is different from hydrogen and methyl.

~~12~~ 13. (Currently Amended) The compound as claimed in claim 1 of the general formula Ia



(Ia)

in which n, R^1, R^2, R^3, R^a and R^b have the meanings given in claim 1 and in which either

A_1, A_2 and A_3 are, independently of each other, N or CH and one or two of the variables A_1, A_2 and A_3 can also be C-R^a, with A_1, A_2 and A_3 not simultaneously being N or simultaneously being selected from CH and C-R^a,

X and Y are selected from CH, C-$R^{b'}$ and N, in which $R^{b'}$ is halogen, methyl, CN, difluoromethyl or trifluoromethyl, with X and Y not simultaneously being N or simultaneously being C-$R^{b'}$, and

k is 0 or 1.

~~13~~ 14. (Currently Amended) The compound of the formula Ia as claimed in claim ~~12~~ 13, in which k = 0, with A_1, A_2 and A_3 being, independently of each other, N or CH and A_1, A_2 and A_3 not simultaneously being N or simultaneously being CH.

~~14~~ 15. (Currently Amended) The compound of the formula Ia as claimed in claim ~~13~~ 14, in which A_1 is CH or N, A_2 is CH and A_3 is N.

~~15~~ 16. (Currently Amended) The compound of the formula Ia as claimed in claim ~~12~~ 13, in which k is 1, A_1 is CH or N, A_2 is CH and A_3 is N, and R^a is selected from , C_1-C_4-alkoxy, NH_2, NHR^6, NR^6R^7 and C_1-C_4-haloalkoxy and R^a is bound to the carbon atom adjacent to A_3.

~~16~~ 17. (Currently Amended) The compound of the formula Ia as claimed in ~~any of claims 12 to 15~~ claim 13, in which n is 0 or 1 and, in the case of n = 1, R^2 is bonded to the C

atom of the piperazine ring which is adjacent to the group R^1-N and is a methyl group having the S configuration.

~~17~~ 18. (Currently Amended) The compound of the formula Ia as claimed ~~in one of claims 12 to 16~~ claim 13, in which the radical Ar carries a substituent R^b in the para position and, where appropriate, a further substituent R^b in the meta position or in the ortho position, in each case based on the binding site of the sulfonamide group.

~~18~~ 19. (Currently Amended) The compound of the formula Ia as claimed in ~~one of claims 12 to 17~~ claim 13, in which Ar is phenyl or pyridyl, which radicals possess, where appropriate, one or 2 R^b substituents.

~~19~~ 20. (Currently Amended) The compound of the formula Ia as claimed in ~~one of claims 12 to 18~~ claim 13, in which R^1 is different from hydrogen and methyl.

~~20~~ 21. (Currently Amended) The compound of the formula Ia as claimed in ~~one of claims 12 to 19~~ claim 13, of the general formula Ia.1



(Ia.1)

in which n, X, Y, R^1, R^2, R^3, R^a and R^b have the meanings given in claim ~~12~~ 13 and q is 0, 1 or 2.

~~21~~ 22. (Currently Amended) The compound of the formula Ia as claimed in ~~one of claims 12 to 19~~, claim 13 of the general formula Ia.2



(Ia.2)

in which n, X, Y, R^1, R^2, R^3, R^a and R^b have the meanings given in claim ~~12~~ 13 and q is 0 or 1.

~~22~~ 23. (Currently Amended) A pharmaceutical composition which comprises at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in ~~one of claims 1 to 21~~ claim 1 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances.

~~23~~ 24. (Currently Amended) The use of at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound of the formula I



(I)

in which Q, Ar, n, R^1, R^2 and R^3 have the previously mentioned meanings, of the N-oxides thereof and of the physiologically tolerated acid addition salts thereof for producing a pharmaceutical composition for treating diseases which respond to influencing by dopamine D_3 receptor antagonists or dopamine D_3 agonists.

~~24~~ 25. (Currently Amended) The use as claimed in claim ~~23~~ 24 for treating diseases of the central nervous system.

~~25~~ 26. (Currently Amended) The use as claimed in claim ~~23~~ 24 for treating kidney function disturbances.

~~26~~ 27. (Currently Amended) A method for treating a medical disorder susceptible to treatment with a dopamine D_3 receptor antagonist or a dopamine D_3 agonist, said method comprising administering an effective amount of at least one compound of ~~the formula I in which Q, Ar, n, R^1, R^2 and R^3 have the previously mentioned meanings, or the N-oxides thereof or the physiologically tolerated acid addition salts thereof to~~ claim 1



(I)

to a subject in need thereof.

~~27~~ 28. (Currently Amended) The method as claimed in ~~Claim 26~~ claim 27, wherein the medical disorder is a disease of the central nervous system.

29. (New) The method as claimed in claim 27 wherein the medical disorder is a disturbance of kidney function.